The Triggering Receptor Expressed On Myeloid Cells 2 pipeline drugs market research report outlays comprehensive information on the Triggering Receptor Expressed On Myeloid Cells 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Triggering Receptor Expressed On Myeloid Cells 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
The report also covers products from therapy areas such as Central Nervous System, Oncology, Immunology, and Metabolic Disorders which include the indications Alzheimer’s Disease, Neurodegenerative Diseases, Solid Tumor, Unspecified Immunological Disorders, Inflammation, and Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)). It also reviews key players involved in Triggering Receptor Expressed On Myeloid Cells 2 targeted therapeutics development with respective active and dormant or discontinued products.
The Triggering Receptor Expressed On Myeloid Cells 2 pipeline targets constitutes close to 11 molecules. Out of which, approximately 11 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 1, 1, 1, 5, and 2 respectively.
Triggering Receptor Expressed On Myeloid Cells 2 overview
Triggering receptor expressed on myeloid cells 2 (TREM2) acts as a receptor for lipoprotein particles such as LDL, VLDL, and HDL and for apolipoproteins such as APOA1, APOA2, APOB, APOE, APOE2, APOE3, APOE4, and CLU and enhances their uptake in microglia. TREM2 forms a receptor signaling complex with TYROBP which mediates signaling and cell activation following ligand binding. It acts as a receptor for amyloid-beta protein 42, a cleavage product of the amyloid-beta precursor protein APP, and mediates its uptake and degradation by microglia.
For a complete picture of Triggering Receptor Expressed On Myeloid Cells 2’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.